NKp30/NCR3 Antibody (MM0490-9D31) [DyLight 405]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-11819V
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
CyTOF-ready, Flow Cytometry
Label
DyLight 405 (Excitation = 400 nm, Emission = 420 nm)
Antibody Source
Monoclonal Mouse IgG2 Clone # MM0490-9D31
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for NKp30/NCR3 Antibody (MM0490-9D31) [DyLight 405]
Immunogen
Human recombinant NKp30/NCR3
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2
Description
This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Applications for NKp30/NCR3 Antibody (MM0490-9D31) [DyLight 405]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: NKp30/NCR3
Given its role in NK cell-mediated killing and activation, NKp30 is a potential target for cancer immunotherapies (6). For instance, Bi-specific T cell engagers (BiTE) is one immunotherapy approach targeting the NKp30/B7-H6 interaction where B7-H6-specific BiTE elicits an attack on tumor cells through interferon gamma (IFNgamma) production and T cell cytotoxicity (1). Another potential approach is NKp30-derived chimeric antigen receptors (CARs) where CAR-T cells that express chimeric NKp30 receptors can efficiently attack B7-H6 tumor cells (1,6).
References
1. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The natural cytotoxicity receptors in health and disease. Frontiers in Immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909
2. Uniprot (O14931)
3. Luczo, J. M., Ronzulli, S. L., & Tompkins, S. M. (2021). Influenza A virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44, and NKp30. Viruses, 13(2), 156. https://doi.org/10.3390/v13020156
4. Pazina, T., Shemesh, A., Brusilovsky, M., Porgador, A., & Campbell, K. S. (2017). Regulation of the Functions of natural cytotoxicity receptors by interactions with diverse ligands and alterations in splice variant expression. Frontiers in Immunology, 8, 369.
5. Kaifu, T., Escaliere, B., Gastinel, L. N., Vivier, E., & Baratin, M. (2011). B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cellular and Molecular Life Sciences : CMLS, 68(21), 3531-3539. https://doi.org/10.1007/s00018-011-0802-7
6. Pinheiro, P. F., Justino, G. C., & Marques, M. M. (2020). NKp30 - A prospective target for new cancer immunotherapy strategies. British Journal of Pharmacology, 177(20), 4563-4580. https://doi.org/10.1111/bph.15222
Alternate Names
CD337, NCR3
Gene Symbol
NCR3
Additional NKp30/NCR3 Products
Product Documents for NKp30/NCR3 Antibody (MM0490-9D31) [DyLight 405]
Product Specific Notices for NKp30/NCR3 Antibody (MM0490-9D31) [DyLight 405]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...